(MCRB) Seres Therapeutics - Overview
Stock: Live Biotherapeutics, Infections, Ulcerative Colitis, Liver Disease
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 116% |
| Relative Tail Risk | -10.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.40 |
| Alpha | -27.83 |
| Character TTM | |
|---|---|
| Beta | 1.037 |
| Beta Downside | 0.841 |
| Drawdowns 3y | |
|---|---|
| Max DD | 94.83% |
| CAGR/Max DD | -0.53 |
Description: MCRB Seres Therapeutics January 17, 2026
Seres Therapeutics (NASDAQ:MCRB) is a clinical-stage biotech focused on live biotherapeutic products that modulate the gut microbiome to prevent infection-related complications in high-risk patients. Its lead candidate, SER-155, is an oral formulation intended to decolonize pathogenic bacteria and strengthen the intestinal barrier in recipients of allogeneic hematopoietic stem cell transplants, aiming to reduce bloodstream infections. The pipeline also includes SER-147 for metabolic-disease-related infections, and SER-287 and SER-301, both in Phase 2 trials for mild-to-moderate ulcerative colitis.
Key operational metrics (as of the latest 10-Q) show a cash balance of roughly $120 million and a quarterly cash burn of about $30 million, giving the company an estimated runway of 3-4 years without additional financing. The microbiome therapeutics market is projected to expand at a ~20 % CAGR through 2030, driven by growing clinical evidence and increasing payer interest in disease-modifying microbiome interventions. A material driver of Seres’ valuation is its ability to secure partnership funding-its prior collaboration with Roche on SER-287 underscored the importance of strategic alliances for advancing costly Phase 2/3 programs.
For a deeper quantitative assessment, you may explore ValueRay’s analyst dashboards.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: 5.39m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA 72.33 > 1.0 |
| NWC/Revenue: 461.2% < 20% (prev 12.6k%; Δ -12.2k% < -1%) |
| CFO/TA -0.16 > 3% & CFO -23.1m > Net Income 5.39m |
| Net Debt (37.6m) to EBITDA (9.67m): 3.89 < 3 |
| Current Ratio: 2.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (8.77m) vs 12m ago 14.92% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 3.92% > 50% (prev 0.04%; Δ 3.88% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' -15.00
| A: 0.20 (Total Current Assets 51.5m - Total Current Liabilities 22.4m) / Total Assets 143.5m |
| B: -6.67 (Retained Earnings -957.1m / Total Assets 143.5m) |
| C: 0.03 (EBIT TTM 5.39m / Avg Total Assets 161.1m) |
| D: -9.59 (Book Value of Equity -957.1m / Total Liabilities 99.8m) |
| Altman-Z'' Score: -30.26 = D |
Beneish M 1.00
| DSRI: 0.00 (Receivables 777.0k/8.67m, Revenue 6.31m/64.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.05 (AQ_t 0.06 / AQ_t-1 0.06) |
| SGI: 98.58 (Revenue 6.31m / 64.0k) |
| TATA: 0.20 (NI 5.39m - CFO -23.1m) / TA 143.5m) |
| Beneish M-Score: 66.35 (Cap -4..+1) = D |
What is the price of MCRB shares?
Over the past week, the price has changed by -6.43%, over one month by -10.23%, over three months by +0.72% and over the past year by -10.63%.
Is MCRB a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the MCRB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21 | 50.4% |
| Analysts Target Price | 21 | 50.4% |
| ValueRay Target Price | 8.7 | -37.4% |
MCRB Fundamental Data Overview February 04, 2026
P/E Forward = 10.2564
P/S = 390.4694
P/B = 3.0868
P/EG = -0.11
Revenue TTM = 6.31m USD
EBIT TTM = 5.39m USD
EBITDA TTM = 9.67m USD
Long Term Debt = 85.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.92m USD (from shortTermDebt, last quarter)
Debt = 85.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 37.6m USD (from netDebt column, last quarter)
Enterprise Value = 174.7m USD (137.1m + Debt 85.3m - CCE 47.6m)
Interest Coverage Ratio = unknown (Ebit TTM 5.39m / Interest Expense TTM 0.0)
EV/FCF = -7.47x (Enterprise Value 174.7m / FCF TTM -23.4m)
FCF Yield = -13.38% (FCF TTM -23.4m / Enterprise Value 174.7m)
FCF Margin = -370.4% (FCF TTM -23.4m / Revenue TTM 6.31m)
Net Margin = 85.50% (Net Income TTM 5.39m / Revenue TTM 6.31m)
Gross Margin = unknown ((Revenue TTM 6.31m - Cost of Revenue TTM 20.9m) / Revenue TTM)
Tobins Q-Ratio = 1.22 (Enterprise Value 174.7m / Total Assets 143.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 85.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = 4.26m (EBIT 5.39m * (1 - 21.00%))
Current Ratio = 2.30 (Total Current Assets 51.5m / Total Current Liabilities 22.4m)
Debt / Equity = 1.95 (Debt 85.3m / totalStockholderEquity, last quarter 43.7m)
Debt / EBITDA = 3.89 (Net Debt 37.6m / EBITDA 9.67m)
Debt / FCF = -1.61 (negative FCF - burning cash) (Net Debt 37.6m / FCF TTM -23.4m)
Total Stockholder Equity = 35.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.35% (Net Income 5.39m / Total Assets 143.5m)
RoE = 15.31% (Net Income TTM 5.39m / Total Stockholder Equity 35.2m)
RoCE = 4.48% (EBIT 5.39m / Capital Employed (Equity 35.2m + L.T.Debt 85.3m))
RoIC = 12.10% (NOPAT 4.26m / Invested Capital 35.2m)
WACC = 6.00% (E(137.1m)/V(222.3m) * Re(9.74%) + D(85.3m)/V(222.3m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 16.50%
Fair Price DCF = unknown (Cash Flow -23.4m)
EPS Correlation: 2.31 | EPS CAGR: 17.16% | SUE: 0.61 | # QB: 0
Revenue Correlation: -35.15 | Revenue CAGR: -55.35% | SUE: -1.58 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.75 | Chg30d=+0.725 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=-10.43 | Chg30d=-0.740 | Revisions Net=-1 | Growth EPS=-1454.5% | Growth Revenue=-100.0%